FIVE PRIME THERAPEUTICS INC's ticker is FPRX and the CUSIP is 33830X104. A total of 57 filers reported holding FIVE PRIME THERAPEUTICS INC in Q1 2014. The put-call ratio across all filers is - and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q1 2021 | $25,202,000 | +135.3% | 669,035 | +6.2% | 0.00% | +100.0% |
| Q4 2020 | $10,711,000 | +322.5% | 629,692 | +16.7% | 0.00% | – |
| Q3 2020 | $2,535,000 | -16.3% | 539,456 | +8.7% | 0.00% | -100.0% |
| Q2 2020 | $3,027,000 | +147.5% | 496,260 | -7.9% | 0.00% | – |
| Q1 2020 | $1,223,000 | -74.2% | 538,789 | -47.8% | 0.00% | – |
| Q4 2019 | $4,734,000 | +162.4% | 1,031,648 | +121.6% | 0.00% | – |
| Q3 2019 | $1,804,000 | -33.6% | 465,597 | +3.4% | 0.00% | -100.0% |
| Q2 2019 | $2,715,000 | -52.7% | 450,414 | +5.1% | 0.00% | 0.0% |
| Q1 2019 | $5,740,000 | -24.7% | 428,389 | -47.7% | 0.00% | 0.0% |
| Q4 2018 | $7,620,000 | +47.5% | 819,402 | +120.8% | 0.00% | 0.0% |
| Q3 2018 | $5,165,000 | -10.4% | 371,100 | +1.8% | 0.00% | -50.0% |
| Q2 2018 | $5,764,000 | +1.9% | 364,656 | +10.7% | 0.00% | 0.0% |
| Q1 2018 | $5,657,000 | -1.3% | 329,347 | +25.9% | 0.00% | 0.0% |
| Q4 2017 | $5,732,000 | -46.1% | 261,527 | +0.7% | 0.00% | -50.0% |
| Q3 2017 | $10,625,000 | +45.7% | 259,735 | +7.2% | 0.00% | +33.3% |
| Q2 2017 | $7,292,000 | -15.8% | 242,188 | +1.1% | 0.00% | -25.0% |
| Q1 2017 | $8,662,000 | -31.0% | 239,635 | -4.3% | 0.00% | -33.3% |
| Q4 2016 | $12,548,000 | -1.7% | 250,427 | +2.9% | 0.01% | 0.0% |
| Q3 2016 | $12,768,000 | +39.1% | 243,266 | +9.6% | 0.01% | +20.0% |
| Q2 2016 | $9,178,000 | +20.0% | 221,969 | +17.9% | 0.01% | +25.0% |
| Q1 2016 | $7,647,000 | +0.4% | 188,218 | +2.5% | 0.00% | 0.0% |
| Q4 2015 | $7,616,000 | +260.4% | 183,539 | +33.7% | 0.00% | +300.0% |
| Q3 2015 | $2,113,000 | -34.3% | 137,326 | +6.1% | 0.00% | -50.0% |
| Q2 2015 | $3,216,000 | -0.3% | 129,487 | -8.3% | 0.00% | 0.0% |
| Q1 2015 | $3,226,000 | +67.4% | 141,241 | +97.9% | 0.00% | +100.0% |
| Q4 2014 | $1,927,000 | +208.8% | 71,377 | +34.0% | 0.00% | – |
| Q3 2014 | $624,000 | -24.6% | 53,263 | -0.0% | 0.00% | -100.0% |
| Q2 2014 | $828,000 | -7.3% | 53,270 | +17.2% | 0.00% | 0.0% |
| Q1 2014 | $893,000 | +80.0% | 45,471 | +53.8% | 0.00% | – |
| Q4 2013 | $496,000 | – | 29,572 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Eventide Asset Management | 601,000 | $24,587,000 | 1.39% |
| HealthCor Management, L.P. | 1,010,930 | $41,357,000 | 1.39% |
| INTERNATIONAL BIOTECHNOLOGY TRUST PLC | 86,500 | $3,535,000 | 1.38% |
| PURA VIDA INVESTMENTS, LLC | 75,000 | $3,068,000 | 0.90% |
| BB BIOTECH AG | 777,500 | $31,808,000 | 0.88% |
| AWM Investment Company, Inc. | 100,000 | $4,091,000 | 0.71% |
| Granite Point Capital Management, L.P. | 50,000 | $2,046,000 | 0.43% |
| Rock Springs Capital Management LP | 217,700 | $8,906,000 | 0.41% |
| Crestline Management, LP | 50,919 | $2,083,000 | 0.29% |
| ADAGE CAPITAL PARTNERS GP, L.L.C. | 2,432,700 | $99,522,000 | 0.24% |